October 2016

Contents

Editorial

• September/October 2016: Volume 17 Number 9/10

Conference reports

• 18th International Workshop on Comorbidities, 12-13 September, New York, USA

• Fanconi-like lab abnormalities reported with daily PrEP: shows importance of routine kidney monitoring

• Bone loss with PrEP in MSM aged 18-24

• Neurological side effects with integrase inhibitors cause low rates of discontinuation in clinical practice

• Atripla three days a week for two years: pilot switch study reports undetectable viral load with better bone, kidneys and sleep

• Raltegravir increases waist circumference more than boosted PIs: greater with use of later ART

• Exercise associated with significantly reduced risk of serious health problems and higher CD4 counts in large multicentre US study

• 21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa

• Four day a week ART: sub-optimal drug levels but few virological failures

• Large disparities in costs of antiretrovirals between low- and middle-income countries

• High risk of virological failure and loss to follow up postpartum in South Africa

• Birth weight and preterm delivery outcomes of vertically vs non-vertically infected HIV positive pregnant women

• High death rates among HIV positive women postpartum accessing ARVs

• Higher rates of eye complications in HIV positive people on ART

• Short reports on selected Durban posters

• Global HIV Clinical Forum: Integrase Inhibitors, 16 July 2016, Durban

• Raltegravir-based third-line ART in children and adolescents

• 8th International Workshop on HIV Paediatrics, 15-16 July 2016. Durban, South Africa

• Raltegravir in HIV-exposed neonates

• Virological response without routine viral load monitoring in children: results from the ARROW trial

• Tenofovir-containing ART reduces bone mineral density in breast feeding women: results from IMPAACT P1084s

Antiretrovirals

• First generic TDF/FTC approved in EU

• Single-pill PI-based combination submitted to EMA

• Dolutegravir superior to standard dose efavirenz in WHO analysis

Treatment access

• First generic version of dolutegravir approved by the FDA

• Brazil to start using dolutegravir first-line in its national programme

• Global Fund to reach US $13 billion target for 2017-2019: UK pledges up to $1.3 billion

Guidelines

• US DHHS guidelines updated (July 2016)

HIV prevention and transmission

• PrEP update: EU approval, extended access for PROUD participants, TAF studies underway

Cure-related research

• HIV persistence: defective virus copies accumulate rapidly after infection

On the web

• Conference materials and online publications

PDFs

• September/October 2016: Volume 17 Number 9/10